{"ticker": {"uuid": "90e83a5e-5a49-4be6-a760-db48574024c1", "symbol": "PHVS", "name": "Pharvaris BV", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Pharvaris publishes review on bradykinin B2 receptor research", "summary": "Pharvaris (NASDAQ:PHVS) has published a review article in Clinical Reviews in Allergy & Immunology discussing the biology of bradykinin and the bradykinin B2 receptor. The article examines the scientific and clinical research supporting bradykinin B2 receptor antagonism as a ther", "url": "https://www.investing.com/news/company-news/pharvaris-publishes-review-on-bradykinin-b2-receptor-research-93CH-4805322", "source_name": "Investing.com", "published_at": "2026-07-22T11:19:55", "published_display": "22 Jul 2026 11:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) Could Be 92% Undervalued On FDA NDA Acceptance", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-20T17:04:15+00:00", "published_display": "20 Jul 2026 17:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(PHVS) Movement as an Input in Quant Signal Sets", "summary": "This article analyzes Pharvaris N.v. (NASDAQ: PHVS) using AI models, identifying a weak near-term sentiment despite long-term strength. It outlines specific trading strategies including position, momentum breakout, and risk hedging, complete with entry points, targets, and stop l", "url": "https://news.stocktradersdaily.com/news_release/14/PHVS_Movement_as_an_Input_in_Quant_Signal_Sets_072026051002_1784581802.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-20T17:10:00", "published_display": "20 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did FDA\u2019s NDA Acceptance for Deucrictibant Just Shift Pharvaris' (PHVS) Hereditary Angioedema Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1iMXFPVnB1QUF4VzFqXzRXZTFqMWl3cjFOU1Y5MHRUME9aMUtETlhoNnRrRnQ3RXpQZWVOR19KMHBVMTR2cWVMakk0M1k2UkRKcGp6aGttWDc?oc=5", "source_name": "webull.com", "published_at": "2026-07-17T00:00:00+00:00", "published_display": "17 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOU3k3Z2J6S1ZCRHN5OHVwLXdkUExjSHNsQXVDei1IcGhHMjZsamF1aEt1c0R0OHJpS3A2Sm1qUUFJTGFuLVRHcUJnOW9RV28tbGdFVXlIWVJSTHUwR0JnM0MzVlNoeElHZ0FCWWU3UmVTVV9xbjc3MWItZ3NNaXp3Y0R4RTZRbjBlWDdTZ0RBSWprZw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T16:00:03+00:00", "published_display": "15 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Initiates Coverage on Pharvaris With Overweight Rating, $55 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wells-fargo-initiates-coverage-pharvaris-112047684.html", "source_name": "MT Newswires", "published_at": "2026-07-15T11:20:47+00:00", "published_display": "15 Jul 2026 11:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo initiates Pharvaris stock with Overweight rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSXdfb3VycGUwUlZPZWh1ZE5DdTMwMmFLQ2xXaFYzeVFYRmczVUdQMjJsTVdFTkF5UExXU0tfc2ZfSk1LbUdDS0FoUzVPQ3k1RkNYNG1yc3NKTzNDQU41dFFObWpad0dyMXhGUnppMzA1am9mUldzUUltR25CWUYyVVNORW1qR3gzdXpqaU9jSlVTMGFPMTFreDE1UmloWGdSY2FIYlBGVDBBenNPRzlENXhRenozQTdRNzMzYg?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T10:27:04+00:00", "published_display": "15 Jul 2026 10:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) CMO Lu Peng reports 226-share tax withholding event", "summary": "Pharvaris N.V. Chief Medical Officer Lu Peng reported a tax withholding event involving 226 common shares at $35.07 per share. These shares were withheld to cover tax obligations arising from the vesting of restricted stock units. After this transaction, Lu Peng directly holds 65", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-fc1f2ee00084.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:47:23", "published_display": "14 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAJBVV95cUxQTTVGSFNzZjNVanhtbnlXWGxFZ0ZBU3V2WWNFSFRiQ21NcTBNUnF2REhVYk51bjAtcTB3S2NkeFZ2TXZhcWplTWlOV01YbUZrZHVjQzNZWVc4YmRNRHFkV1ZNdEthTldRZEdEUzB1aWFJUDZPSXRHd2xNakVjZzV4MW1pYXVsMkFPWVQyWm91dk92VENVTENqUmJWY3RLX1UyT1lqdm1nUUk5d3UxYXlzUnlYdnRKZnBqUmVXZVBqa0pVajN4TXY4U3BXc3hoVy1zR09CempHNW5ZRHI1eVBESzV6NS1JREVON3M5UXgzN3p2OUVKQ3NRbTB4NTNWbDdhSmIxVXJPel9jZXdvemVNNi0xVno?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-07-14T16:24:48+00:00", "published_display": "14 Jul 2026 16:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Pharvaris N.V. For: 13 July By Investing.com", "summary": "Investing.com published a Form 144 filing for Pharvaris N.V. (PHVS) on July 13, 2026. This announcement indicates a notice of proposed sale of securities, although the specific details of the transaction are not provided in this brief update. The article provides the date of the ", "url": "https://ng.investing.com/news/stock-market-news/form-144-pharvaris-nv-for-13-july-93CH-2597609", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T21:41:12", "published_display": "13 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) holder Berndt Modig files to sell 2,292 shares", "summary": "Pharvaris (PHVS) shareholder Berndt Modig has filed a Form 144 to sell up to 2,292 shares of common stock, valued at approximately $80,380.44, through Morgan Stanley Smith Barney LLC on July 13, 2026. These shares are related to Restricted Stock Units dated July 11, 2026. The fil", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-25f73d7036eb.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:12", "published_display": "13 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks", "summary": "The FDA has accepted Pharvaris'z NDA for deucrictibant IR, an oral bradykinin B2 receptor antagonist, for the on-demand treatment of hereditary angioedema (HAE) attacks. The PDUFA target action date is April 23, 2027. This acceptance is based on positive results from the Phase 3 ", "url": "https://www.contemporarypediatrics.com/view/fda-accepts-deucrictibant-ir-application-hereditary-angioedema", "source_name": "Contemporary Pediatrics", "published_at": "2026-07-07T06:41:02", "published_display": "07 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris Says FDA Accepted New Drug Application for Potential Treatment for Hereditary Angioedema Attacks", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pharvaris-says-fda-accepted-drug-112206927.html", "source_name": "MT Newswires", "published_at": "2026-07-06T11:22:06+00:00", "published_display": "06 Jul 2026 11:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pharvaris-announces-fda-acceptance-drug-105000286.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T10:50:00+00:00", "published_display": "06 Jul 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris wins FDA review for oral HAE attack treatment", "summary": "Pharvaris announced that the FDA has accepted its New Drug Application (NDA) for deucrictibant IR 20 mg capsules, an on-demand treatment for hereditary angioedema (HAE) attacks, setting a PDUFA target action date of April 23, 2027. The application is supported by data from over 1", "url": "https://www.stocktitan.net/news/PHVS/pharvaris-announces-fda-acceptance-of-new-drug-application-for-4n5lqp57q338.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:11:34", "published_display": "06 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS - Pharvaris NV Latest SEC Filings", "summary": "This article provides a detailed financial overview and snapshot of Pharvaris NV (PHVS), a biotechnology company. It includes key financial metrics such as market cap, enterprise value, income, sales, various ratios, and performance indicators. The filing also lists insider and i", "url": "https://finviz.com/stock?t=PHVS&ty=lf&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-03T18:10:58", "published_display": "03 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS - Pharvaris NV Options", "summary": "This article provides an overview of Pharvaris NV (PHVS) stock options and key financial data. It details market capitalization, enterprise value, income, sales, per-share metrics, profitability ratios, and various performance indicators. The data includes analyst recommendations", "url": "https://finviz.com/stock?t=PHVS&ty=oc&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-03T10:09:59", "published_display": "03 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS - Pharvaris NV Volatility & Greeks", "summary": "This article provides an overview of Pharvaris NV (PHVS) financial metrics, including key statistics, performance indicators, and volatility measures as of July 2, 2026. It presents a snapshot of the company's market capitalization, income, sales, and various financial ratios, al", "url": "https://finviz.com/stock?t=PHVS&ta=1&p=m&ty=ocv&r=max&ov=chain_strike&s=35", "source_name": "Finviz", "published_at": "2026-07-02T04:39:26", "published_display": "02 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris Insider Sold Shares Worth $1,331,496, According to a Recent SEC Filing", "summary": "An insider at Pharvaris N.V. (PHVS) sold shares worth $1,331,496, as reported in a recent SEC filing. This transaction, published on July 2, 2026, by MT Newswires, is part of several insider share disposals noted by MarketScreener for the biopharmaceutical company. Pharvaris focu", "url": "https://www.marketscreener.com/news/pharvaris-insider-sold-shares-worth-1-331-496-according-to-a-recent-sec-filing-ce7f5fd2d18af525", "source_name": "www.marketscreener.com", "published_at": "2026-07-02T04:22:00", "published_display": "02 Jul 2026 04:22", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells 37,600 Shares of Pharvaris NV (PHVS)", "summary": "A director at Pharvaris NV (PHVS), Schikan Johannes Gerardus Christiaan Petrus, sold 37,600 shares of the company on June 30, 2026, reducing his holdings to 315,167 shares. This transaction is part of a pattern where the insider has sold a total of 80,000 shares over the past yea", "url": "https://www.gurufocus.com/news/8942161/insider-sell-schikan-johannes-gerardus-christiaan-petrus-sells-37600-shares-of-pharvaris-nv-phvs", "source_name": "GuruFocus", "published_at": "2026-07-02T02:10:35", "published_display": "02 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares", "summary": "Pharvaris N.V. executive Anne Lesage exercised options to acquire 37,572 shares and subsequently sold 76,172 shares of common stock at weighted average prices around $35 per share. These were pre-scheduled transactions under a Rule 10b5-1 trading plan, involving cashless exercise", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-b49389229382.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:10:35", "published_display": "01 Jul 2026 23:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan", "summary": "A director at Pharvaris N.V. (PHVS), Johannes Gerardus Christiaan Petrus Schikan, sold a total of 37,600 common shares in open-market transactions on June 29 and June 30, 2026, under a Rule 10b5-1 trading plan. The shares were sold at weighted average prices of $35.0533 and $35.4", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-f9d4605315b6.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:10:35", "published_display": "01 Jul 2026 23:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144: Hans H. Schikan 10b5-1 sales listed for PHVS (PHVS)", "summary": "A recently filed Form 144 for Pharvaris N.V. (PHVS) indicates proposed sales of Common shares linked to Founders Shares. The filing also details recent 10b5-1 sales by Hans H. Schikan, including transactions on June 29, 2026, for 6,888 shares valued at $241,447.13, and on April 3", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-9f0951e660b0.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:10:35", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS (NASDAQ) insiders executed multiple 10b5-1 sales in 2026", "summary": "PHVS insider Anne Simonne J. Lesage and Graymatters Consulting B.V. executed multiple pre-arranged 10b5-1 sales of Common stock throughout 2026, as detailed in a recent Form 144 SEC filing. These sales occurred on various dates, including 21,700 shares on April 30, 2026, and 8,30", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-09f2099e6ed1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:10:35", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS insiders (PHVS) list option exercise and multiple 10b5-1 sales in June 2026", "summary": "A recent SEC Form 144 filing indicates that insiders of Pharvaris N.V. (PHVS) have engaged in an option exercise and multiple pre-arranged 10b5-1 stock sales between April and June 2026. Key sellers include Anne Simonne J. Lesage and Graymatters Consulting B.V., with significant ", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-ec4ed3df0347.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:10:35", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS (NASDAQ: PHVS) 10b5-1 sales logged; Form 144 for 6,888 shares", "summary": "Pharvaris N.V. (PHVS) has filed a Form 144, indicating a proposed sale of 6,888 \"Founders Shares\" by an affiliated holder. The filing also details several past 10b5-1 sales executed by Hans H. Schikan, a company insider, on various dates in April and June 2026, totaling a signifi", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-39bafe8071ab.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:39:30", "published_display": "30 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan", "summary": "Pharvaris N.V.'s Chief Medical Officer, Lu Peng, executed a pre-arranged sale of 29,700 shares of common stock on June 25-26, 2026, after exercising stock options at $2.59 per share. The shares were sold under a Rule 10b5-1 trading plan via cashless exercises, with weighted avera", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-0c0832377532.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:39:29", "published_display": "30 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) exec\u2019s 10b5-1 option exercise and 4,600-share sale", "summary": "Pharvaris N.V. executive Anne Lesage, Chief Early Development, conducted a scheduled option exercise and sold a total of 4,600 common shares on June 25, 2026, under a Rule 10b5-1 trading plan. The sales, occurring at weighted average prices around $35.12 per share, were linked to", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-1b7b54018aea.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:39:29", "published_display": "30 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) director\u2019s 2,400-share Rule 10b5-1 stock sale detailed", "summary": "Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan sold 2,400 shares of the company's common stock at a weighted average price of $35.1041 per share through a pre-arranged Rule 10b5-1 trading plan. The individual sale prices ranged from $35.00 to $35.30. After th", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-9a005489ec3e.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:34:29", "published_display": "30 Jun 2026 03:34", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells Shares of Pharvaris NV (PHVS)", "summary": "Schikan Johannes Gerardus Christiaan Petrus, a Director at Pharvaris NV (PHVS), sold 2,400 shares of the company on June 29, 2026. Following this transaction, he now holds 352,767 shares. Pharvaris NV, a clinical-stage company, focuses on developing oral therapies for hereditary ", "url": "https://www.gurufocus.com/news/8937321/insider-sell-schikan-johannes-gerardus-christiaan-petrus-sells-shares-of-pharvaris-nv-phvs", "source_name": "GuruFocus", "published_at": "2026-06-30T00:39:29", "published_display": "30 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Pharvaris N.V. For: 29 June By Investing.com", "summary": "This article announces the filing of Form 144 for Pharvaris N.V. on June 29. It is a brief notice published by Investing.com, providing basic financial data like the company's stock symbol and current price movement, along with various financial market indices and commodity price", "url": "https://za.investing.com/news/stock-market-news/form-144-pharvaris-nv-for-29-june-93CH-4348648", "source_name": "Investing.com South Africa", "published_at": "2026-06-29T21:40:24", "published_display": "29 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pharvaris N.V. \u2013 GETTEX:9EN", "summary": "This article displays the \"Price to book forward\" metric for Pharvaris N.V. (9EN) on the Gettex exchange, as provided by TradingView. It shows the period, value, and change percentages for this financial indicator. The content is primarily a data placeholder within a financial pl", "url": "https://www.tradingview.com/symbols/GETTEX-9EN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T17:39:29", "published_display": "29 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS holders execute multiple 10b5-1 sales (NASDAQ: PHVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOODhVZEpReXhUTW9WNU9rSTdBQU80d0E4bzFheG91TERFcVQzcFl5R0ZEREVDbHNsbzBnMmJwNlp3M2l6R081c1Nqb3NYUEZ4d3pQTzRBZ3pWOGRvVFBuOU9LeEpxSk1UUzdtTjlWQURBTENXVldrUktiSGREdEdpV21UTXpQdzdKOHJ6OXh1bm9pMmot?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (PHVS) Price Events", "summary": "This article provides a detailed liquidity mapping and analysis for Pharvaris N.v. (NASDAQ: PHVS), indicating strong sentiment and compelling upside potential. It outlines three AI-generated institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014al", "url": "https://news.stocktradersdaily.com/news_release/9/Liquidity_Mapping_Around_PHVS_Price_Events_062826083803_1782650283.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T08:38:00", "published_display": "28 Jun 2026 08:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pharvaris N.V. \u2013 NASDAQ:PHVS", "summary": "This article displays the \"Price to book forward\" metric for Pharvaris N.V. (NASDAQ: PHVS) on TradingView. It provides a specific period value and changes in percentage. The content is presented as part of the financial overview for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-PHVS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:39:55", "published_display": "28 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris N.V. Actuals & Estimates (NASDAQ:PHVS)", "summary": "This article provides an overview of Pharvaris N.V. (PHVS) stock performance, financial estimates, and key metrics. It details the current stock price, historical highs and lows, analyst forecasts, and upcoming earnings report dates. The article also covers market capitalization,", "url": "https://www.tradingview.com/symbols/NASDAQ-PHVS/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T08:09:14", "published_display": "27 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pharvaris N.V. \u2013 LS:A2QNWS", "summary": "The article provides a financial overview for Pharvaris N.V. (LS:A2QNWS), focusing on its enterprise value to revenue forward. It appears to be an entry from a financial data platform, presenting financial metrics without detailed textual analysis. The content is primarily a list", "url": "https://www.tradingview.com/symbols/LS-A2QNWS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:09:14", "published_display": "27 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pharvaris N.V. Prices Underwritten Offering of 3,874,664 Ordinary Shares at $29.68 Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQa0xIOUlQd0htd3ZfS2xoeHBiU3N6MGxXUjNmcDgtWWNRVm11SjVBWHpLMm5WU1h5RUxtSGtpcTl6TTRpVlR5ck12RklPYTE2M2phM0kyVm9hejRuMDdyVlFyejk2UWRuM3BfSjN6R2g3NkJEZjZCVERtMzVFRkdIZDFNYkV4VEUwMFhYeHB1UmZ5SWdISFpDWmkzclc3NWtiaEZDQ2tIV3FJWTRQV3FpbmxVVEdmYnFVOTFhZlltNlgwY3lReTBzYnU5RQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PHVS Stock Price and Chart \u2014 NASDAQ:PHVS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5wZTk5MlQwWHcxSG9yallCMjRCVUpGdWFGXzlDWEQ3cE1FYmxCQVdCczhJLXk4LVVwb1J0RzF1NVpWVWgwb1RvWE0ydUJvbnA0a3V3aDZXUnpmQjZr?oc=5", "source_name": "TradingView", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNT0xUTVFPWDZRMmFBekpnaTBXN1FvV3cwSzVQcWdqZUIzZVJmaExyeWxmQWU5Y29PcDA2TmM5OFFEWGhXX2Z4dW9HVmVUeWdLRjB1V2xVc2hHQXdtSlJGOXN3blF4TnRNYlk0NDl5X2txVzRtbFlxVzNnYTE1NS15UTBB?oc=5", "source_name": "Market source", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Pharvaris publishes review on bradykinin B2 receptor research", "summary": "Pharvaris (NASDAQ:PHVS) has published a review article in Clinical Reviews in Allergy & Immunology discussing the biology of bradykinin and the bradykinin B2 receptor. The article examines the scientific and clinical research supporting bradykinin B2 receptor antagonism as a ther", "url": "https://www.investing.com/news/company-news/pharvaris-publishes-review-on-bradykinin-b2-receptor-research-93CH-4805322", "source_name": "Investing.com", "published_at": "2026-07-22T11:19:55", "published_display": "22 Jul 2026 11:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) Could Be 92% Undervalued On FDA NDA Acceptance", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-20T17:04:15+00:00", "published_display": "20 Jul 2026 17:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(PHVS) Movement as an Input in Quant Signal Sets", "summary": "This article analyzes Pharvaris N.v. (NASDAQ: PHVS) using AI models, identifying a weak near-term sentiment despite long-term strength. It outlines specific trading strategies including position, momentum breakout, and risk hedging, complete with entry points, targets, and stop l", "url": "https://news.stocktradersdaily.com/news_release/14/PHVS_Movement_as_an_Input_in_Quant_Signal_Sets_072026051002_1784581802.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-20T17:10:00", "published_display": "20 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did FDA\u2019s NDA Acceptance for Deucrictibant Just Shift Pharvaris' (PHVS) Hereditary Angioedema Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1iMXFPVnB1QUF4VzFqXzRXZTFqMWl3cjFOU1Y5MHRUME9aMUtETlhoNnRrRnQ3RXpQZWVOR19KMHBVMTR2cWVMakk0M1k2UkRKcGp6aGttWDc?oc=5", "source_name": "webull.com", "published_at": "2026-07-17T00:00:00+00:00", "published_display": "17 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOU3k3Z2J6S1ZCRHN5OHVwLXdkUExjSHNsQXVDei1IcGhHMjZsamF1aEt1c0R0OHJpS3A2Sm1qUUFJTGFuLVRHcUJnOW9RV28tbGdFVXlIWVJSTHUwR0JnM0MzVlNoeElHZ0FCWWU3UmVTVV9xbjc3MWItZ3NNaXp3Y0R4RTZRbjBlWDdTZ0RBSWprZw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T16:00:03+00:00", "published_display": "15 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Initiates Coverage on Pharvaris With Overweight Rating, $55 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wells-fargo-initiates-coverage-pharvaris-112047684.html", "source_name": "MT Newswires", "published_at": "2026-07-15T11:20:47+00:00", "published_display": "15 Jul 2026 11:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo initiates Pharvaris stock with Overweight rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSXdfb3VycGUwUlZPZWh1ZE5DdTMwMmFLQ2xXaFYzeVFYRmczVUdQMjJsTVdFTkF5UExXU0tfc2ZfSk1LbUdDS0FoUzVPQ3k1RkNYNG1yc3NKTzNDQU41dFFObWpad0dyMXhGUnppMzA1am9mUldzUUltR25CWUYyVVNORW1qR3gzdXpqaU9jSlVTMGFPMTFreDE1UmloWGdSY2FIYlBGVDBBenNPRzlENXhRenozQTdRNzMzYg?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T10:27:04+00:00", "published_display": "15 Jul 2026 10:27", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) CMO Lu Peng reports 226-share tax withholding event", "summary": "Pharvaris N.V. Chief Medical Officer Lu Peng reported a tax withholding event involving 226 common shares at $35.07 per share. These shares were withheld to cover tax obligations arising from the vesting of restricted stock units. After this transaction, Lu Peng directly holds 65", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-fc1f2ee00084.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:47:23", "published_display": "14 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAJBVV95cUxQTTVGSFNzZjNVanhtbnlXWGxFZ0ZBU3V2WWNFSFRiQ21NcTBNUnF2REhVYk51bjAtcTB3S2NkeFZ2TXZhcWplTWlOV01YbUZrZHVjQzNZWVc4YmRNRHFkV1ZNdEthTldRZEdEUzB1aWFJUDZPSXRHd2xNakVjZzV4MW1pYXVsMkFPWVQyWm91dk92VENVTENqUmJWY3RLX1UyT1lqdm1nUUk5d3UxYXlzUnlYdnRKZnBqUmVXZVBqa0pVajN4TXY4U3BXc3hoVy1zR09CempHNW5ZRHI1eVBESzV6NS1JREVON3M5UXgzN3p2OUVKQ3NRbTB4NTNWbDdhSmIxVXJPel9jZXdvemVNNi0xVno?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-07-14T16:24:48+00:00", "published_display": "14 Jul 2026 16:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Pharvaris N.V. For: 13 July By Investing.com", "summary": "Investing.com published a Form 144 filing for Pharvaris N.V. (PHVS) on July 13, 2026. This announcement indicates a notice of proposed sale of securities, although the specific details of the transaction are not provided in this brief update. The article provides the date of the ", "url": "https://ng.investing.com/news/stock-market-news/form-144-pharvaris-nv-for-13-july-93CH-2597609", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T21:41:12", "published_display": "13 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) holder Berndt Modig files to sell 2,292 shares", "summary": "Pharvaris (PHVS) shareholder Berndt Modig has filed a Form 144 to sell up to 2,292 shares of common stock, valued at approximately $80,380.44, through Morgan Stanley Smith Barney LLC on July 13, 2026. These shares are related to Restricted Stock Units dated July 11, 2026. The fil", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-25f73d7036eb.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:12", "published_display": "13 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks", "summary": "The FDA has accepted Pharvaris'z NDA for deucrictibant IR, an oral bradykinin B2 receptor antagonist, for the on-demand treatment of hereditary angioedema (HAE) attacks. The PDUFA target action date is April 23, 2027. This acceptance is based on positive results from the Phase 3 ", "url": "https://www.contemporarypediatrics.com/view/fda-accepts-deucrictibant-ir-application-hereditary-angioedema", "source_name": "Contemporary Pediatrics", "published_at": "2026-07-07T06:41:02", "published_display": "07 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris Says FDA Accepted New Drug Application for Potential Treatment for Hereditary Angioedema Attacks", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pharvaris-says-fda-accepted-drug-112206927.html", "source_name": "MT Newswires", "published_at": "2026-07-06T11:22:06+00:00", "published_display": "06 Jul 2026 11:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pharvaris-announces-fda-acceptance-drug-105000286.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T10:50:00+00:00", "published_display": "06 Jul 2026 10:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris wins FDA review for oral HAE attack treatment", "summary": "Pharvaris announced that the FDA has accepted its New Drug Application (NDA) for deucrictibant IR 20 mg capsules, an on-demand treatment for hereditary angioedema (HAE) attacks, setting a PDUFA target action date of April 23, 2027. The application is supported by data from over 1", "url": "https://www.stocktitan.net/news/PHVS/pharvaris-announces-fda-acceptance-of-new-drug-application-for-4n5lqp57q338.html", "source_name": "Stock Titan", "published_at": "2026-07-06T11:11:34", "published_display": "06 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS - Pharvaris NV Latest SEC Filings", "summary": "This article provides a detailed financial overview and snapshot of Pharvaris NV (PHVS), a biotechnology company. It includes key financial metrics such as market cap, enterprise value, income, sales, various ratios, and performance indicators. The filing also lists insider and i", "url": "https://finviz.com/stock?t=PHVS&ty=lf&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-03T18:10:58", "published_display": "03 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS - Pharvaris NV Options", "summary": "This article provides an overview of Pharvaris NV (PHVS) stock options and key financial data. It details market capitalization, enterprise value, income, sales, per-share metrics, profitability ratios, and various performance indicators. The data includes analyst recommendations", "url": "https://finviz.com/stock?t=PHVS&ty=oc&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-03T10:09:59", "published_display": "03 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS - Pharvaris NV Volatility & Greeks", "summary": "This article provides an overview of Pharvaris NV (PHVS) financial metrics, including key statistics, performance indicators, and volatility measures as of July 2, 2026. It presents a snapshot of the company's market capitalization, income, sales, and various financial ratios, al", "url": "https://finviz.com/stock?t=PHVS&ta=1&p=m&ty=ocv&r=max&ov=chain_strike&s=35", "source_name": "Finviz", "published_at": "2026-07-02T04:39:26", "published_display": "02 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris Insider Sold Shares Worth $1,331,496, According to a Recent SEC Filing", "summary": "An insider at Pharvaris N.V. (PHVS) sold shares worth $1,331,496, as reported in a recent SEC filing. This transaction, published on July 2, 2026, by MT Newswires, is part of several insider share disposals noted by MarketScreener for the biopharmaceutical company. Pharvaris focu", "url": "https://www.marketscreener.com/news/pharvaris-insider-sold-shares-worth-1-331-496-according-to-a-recent-sec-filing-ce7f5fd2d18af525", "source_name": "www.marketscreener.com", "published_at": "2026-07-02T04:22:00", "published_display": "02 Jul 2026 04:22", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells 37,600 Shares of Pharvaris NV (PHVS)", "summary": "A director at Pharvaris NV (PHVS), Schikan Johannes Gerardus Christiaan Petrus, sold 37,600 shares of the company on June 30, 2026, reducing his holdings to 315,167 shares. This transaction is part of a pattern where the insider has sold a total of 80,000 shares over the past yea", "url": "https://www.gurufocus.com/news/8942161/insider-sell-schikan-johannes-gerardus-christiaan-petrus-sells-37600-shares-of-pharvaris-nv-phvs", "source_name": "GuruFocus", "published_at": "2026-07-02T02:10:35", "published_display": "02 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares", "summary": "Pharvaris N.V. executive Anne Lesage exercised options to acquire 37,572 shares and subsequently sold 76,172 shares of common stock at weighted average prices around $35 per share. These were pre-scheduled transactions under a Rule 10b5-1 trading plan, involving cashless exercise", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-b49389229382.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:10:35", "published_display": "01 Jul 2026 23:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan", "summary": "A director at Pharvaris N.V. (PHVS), Johannes Gerardus Christiaan Petrus Schikan, sold a total of 37,600 common shares in open-market transactions on June 29 and June 30, 2026, under a Rule 10b5-1 trading plan. The shares were sold at weighted average prices of $35.0533 and $35.4", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-f9d4605315b6.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:10:35", "published_display": "01 Jul 2026 23:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144: Hans H. Schikan 10b5-1 sales listed for PHVS (PHVS)", "summary": "A recently filed Form 144 for Pharvaris N.V. (PHVS) indicates proposed sales of Common shares linked to Founders Shares. The filing also details recent 10b5-1 sales by Hans H. Schikan, including transactions on June 29, 2026, for 6,888 shares valued at $241,447.13, and on April 3", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-9f0951e660b0.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:10:35", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS (NASDAQ) insiders executed multiple 10b5-1 sales in 2026", "summary": "PHVS insider Anne Simonne J. Lesage and Graymatters Consulting B.V. executed multiple pre-arranged 10b5-1 sales of Common stock throughout 2026, as detailed in a recent Form 144 SEC filing. These sales occurred on various dates, including 21,700 shares on April 30, 2026, and 8,30", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-09f2099e6ed1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:10:35", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS insiders (PHVS) list option exercise and multiple 10b5-1 sales in June 2026", "summary": "A recent SEC Form 144 filing indicates that insiders of Pharvaris N.V. (PHVS) have engaged in an option exercise and multiple pre-arranged 10b5-1 stock sales between April and June 2026. Key sellers include Anne Simonne J. Lesage and Graymatters Consulting B.V., with significant ", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-ec4ed3df0347.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:10:35", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS (NASDAQ: PHVS) 10b5-1 sales logged; Form 144 for 6,888 shares", "summary": "Pharvaris N.V. (PHVS) has filed a Form 144, indicating a proposed sale of 6,888 \"Founders Shares\" by an affiliated holder. The filing also details several past 10b5-1 sales executed by Hans H. Schikan, a company insider, on various dates in April and June 2026, totaling a signifi", "url": "https://www.stocktitan.net/sec-filings/PHVS/144-pharvaris-n-v-sec-filing-39bafe8071ab.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:39:30", "published_display": "30 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan", "summary": "Pharvaris N.V.'s Chief Medical Officer, Lu Peng, executed a pre-arranged sale of 29,700 shares of common stock on June 25-26, 2026, after exercising stock options at $2.59 per share. The shares were sold under a Rule 10b5-1 trading plan via cashless exercises, with weighted avera", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-0c0832377532.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:39:29", "published_display": "30 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) exec\u2019s 10b5-1 option exercise and 4,600-share sale", "summary": "Pharvaris N.V. executive Anne Lesage, Chief Early Development, conducted a scheduled option exercise and sold a total of 4,600 common shares on June 25, 2026, under a Rule 10b5-1 trading plan. The sales, occurring at weighted average prices around $35.12 per share, were linked to", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-1b7b54018aea.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:39:29", "published_display": "30 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris (PHVS) director\u2019s 2,400-share Rule 10b5-1 stock sale detailed", "summary": "Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan sold 2,400 shares of the company's common stock at a weighted average price of $35.1041 per share through a pre-arranged Rule 10b5-1 trading plan. The individual sale prices ranged from $35.00 to $35.30. After th", "url": "https://www.stocktitan.net/sec-filings/PHVS/form-4-pharvaris-n-v-insider-trading-activity-9a005489ec3e.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:34:29", "published_display": "30 Jun 2026 03:34", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells Shares of Pharvaris NV (PHVS)", "summary": "Schikan Johannes Gerardus Christiaan Petrus, a Director at Pharvaris NV (PHVS), sold 2,400 shares of the company on June 29, 2026. Following this transaction, he now holds 352,767 shares. Pharvaris NV, a clinical-stage company, focuses on developing oral therapies for hereditary ", "url": "https://www.gurufocus.com/news/8937321/insider-sell-schikan-johannes-gerardus-christiaan-petrus-sells-shares-of-pharvaris-nv-phvs", "source_name": "GuruFocus", "published_at": "2026-06-30T00:39:29", "published_display": "30 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Pharvaris N.V. For: 29 June By Investing.com", "summary": "This article announces the filing of Form 144 for Pharvaris N.V. on June 29. It is a brief notice published by Investing.com, providing basic financial data like the company's stock symbol and current price movement, along with various financial market indices and commodity price", "url": "https://za.investing.com/news/stock-market-news/form-144-pharvaris-nv-for-29-june-93CH-4348648", "source_name": "Investing.com South Africa", "published_at": "2026-06-29T21:40:24", "published_display": "29 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pharvaris N.V. \u2013 GETTEX:9EN", "summary": "This article displays the \"Price to book forward\" metric for Pharvaris N.V. (9EN) on the Gettex exchange, as provided by TradingView. It shows the period, value, and change percentages for this financial indicator. The content is primarily a data placeholder within a financial pl", "url": "https://www.tradingview.com/symbols/GETTEX-9EN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T17:39:29", "published_display": "29 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS holders execute multiple 10b5-1 sales (NASDAQ: PHVS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOODhVZEpReXhUTW9WNU9rSTdBQU80d0E4bzFheG91TERFcVQzcFl5R0ZEREVDbHNsbzBnMmJwNlp3M2l6R081c1Nqb3NYUEZ4d3pQTzRBZ3pWOGRvVFBuOU9LeEpxSk1UUzdtTjlWQURBTENXVldrUktiSGREdEdpV21UTXpQdzdKOHJ6OXh1bm9pMmot?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (PHVS) Price Events", "summary": "This article provides a detailed liquidity mapping and analysis for Pharvaris N.v. (NASDAQ: PHVS), indicating strong sentiment and compelling upside potential. It outlines three AI-generated institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014al", "url": "https://news.stocktradersdaily.com/news_release/9/Liquidity_Mapping_Around_PHVS_Price_Events_062826083803_1782650283.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T08:38:00", "published_display": "28 Jun 2026 08:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pharvaris N.V. \u2013 NASDAQ:PHVS", "summary": "This article displays the \"Price to book forward\" metric for Pharvaris N.V. (NASDAQ: PHVS) on TradingView. It provides a specific period value and changes in percentage. The content is presented as part of the financial overview for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-PHVS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:39:55", "published_display": "28 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris N.V. Actuals & Estimates (NASDAQ:PHVS)", "summary": "This article provides an overview of Pharvaris N.V. (PHVS) stock performance, financial estimates, and key metrics. It details the current stock price, historical highs and lows, analyst forecasts, and upcoming earnings report dates. The article also covers market capitalization,", "url": "https://www.tradingview.com/symbols/NASDAQ-PHVS/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-27T08:09:14", "published_display": "27 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pharvaris N.V. \u2013 LS:A2QNWS", "summary": "The article provides a financial overview for Pharvaris N.V. (LS:A2QNWS), focusing on its enterprise value to revenue forward. It appears to be an entry from a financial data platform, presenting financial metrics without detailed textual analysis. The content is primarily a list", "url": "https://www.tradingview.com/symbols/LS-A2QNWS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:09:14", "published_display": "27 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris N.V. Prices Underwritten Offering of 3,874,664 Ordinary Shares at $29.68 Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQa0xIOUlQd0htd3ZfS2xoeHBiU3N6MGxXUjNmcDgtWWNRVm11SjVBWHpLMm5WU1h5RUxtSGtpcTl6TTRpVlR5ck12RklPYTE2M2phM0kyVm9hejRuMDdyVlFyejk2UWRuM3BfSjN6R2g3NkJEZjZCVERtMzVFRkdIZDFNYkV4VEUwMFhYeHB1UmZ5SWdISFpDWmkzclc3NWtiaEZDQ2tIV3FJWTRQV3FpbmxVVEdmYnFVOTFhZlltNlgwY3lReTBzYnU5RQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHVS Stock Price and Chart \u2014 NASDAQ:PHVS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5wZTk5MlQwWHcxSG9yallCMjRCVUpGdWFGXzlDWEQ3cE1FYmxCQVdCczhJLXk4LVVwb1J0RzF1NVpWVWgwb1RvWE0ydUJvbnA0a3V3aDZXUnpmQjZr?oc=5", "source_name": "TradingView", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNT0xUTVFPWDZRMmFBekpnaTBXN1FvV3cwSzVQcWdqZUIzZVJmaExyeWxmQWU5Y29PcDA2TmM5OFFEWGhXX2Z4dW9HVmVUeWdLRjB1V2xVc2hHQXdtSlJGOXN3blF4TnRNYlk0NDl5X2txVzRtbFlxVzNnYTE1NS15UTBB?oc=5", "source_name": "Market source", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 49, "sentiment_summary": {"positive": 11, "negative": 9, "neutral": 29, "score": 51, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 17.4, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 34.94, "latest_week": "2026-07-17", "one_week_move": -0.4, "four_week_move": 6.5, "twelve_week_move": 22.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.632121, "market_dynamics_buy_signal": false, "relative_strength": 19.352446, "fair_value_gap": 57.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.4543, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.4% over one week, +6.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 50, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "Stock Traders Daily", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 4}, {"label": "Macro sensitivity", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.4% over one week, +6.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Pharvaris publishes review on bradykinin B2 receptor research"}], "updated_at": "2026-07-22T13:37:32.513261+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}